Abstract:Nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2) is an endogenous axon survival factor that maintains axon health by blocking activation of the downstream pro-degenerative protein SARM1 (sterile alpha and TIR motif containing protein 1). While complete absence of NMNAT2 in mice results in extensive axon truncation and perinatal lethality, the removal of SARM1 completely rescues these phenotypes. Reduced levels of NMNAT2 can be compatible with life, however they compromise axon development and survival. Mice born expressing sub-heterozygous levels of NMNAT2 remain overtly normal into old age but develop axonal defects and as well as behavioural phenotypes. Therefore, it is important to examine the effects of constitutively low NMNAT2 expression on SARM1 activation and disease susceptibility. Here we demonstrate that chronically low NMNAT2 levels reduce prenatal viability in mice in a SARM1-dependent manner and lead to sub-lethal SARM1 activation in morphologically intact axons of superior cervical ganglion (SCG) primary cultures. This is characterised by a depletion in NAD(P) and compromised neurite outgrowth. We also show that chronically low NMNAT2 expression reverses the NAD-enhancing effect of nicotinamide riboside (NR) in axons in a SARM1-dependent manner. These data indicate that low NMNAT2 levels can trigger sub-lethal SARM1 activation which is detectable at the molecular level and could predispose to human axonal disorders.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore whether chronic low - level NMNAT2 expression will lead to the activation of SARM1, and how this activation affects axon health and neuron growth. Specifically, the researchers focused on the following points: 1. **The impact of low NMNAT2 expression on survival rate**: - Through experiments, the researchers found that the survival rate of mice carrying two different NMNAT2 gene - trap alleles (Nmnat2gtE and Nmnat2gtBay) during the embryonic period and after birth was significantly reduced. In particular, the Nmnat2gtBay/gtE mice (i.e., mice expressing sub - heterozygous levels of NMNAT2), their survival rate was significantly lower than the expected value. - Further research shows that knocking out SARM1 can restore the survival rate of these mice, indicating that the decrease in survival rate caused by low NMNAT2 expression is SARM1 - dependent. 2. **The impact of low NMNAT2 expression on SARM1 activation**: - The researchers measured the NAD and NADP levels in primary cultures of the superior cervical ganglion (SCG) from mice of different genotypes. The results showed that the NAD and NADP levels in Nmnat2gtBay/gtE mice were significantly lower than those in wild - type and single - heterozygous mice. - After knocking out SARM1, the NAD and NADP levels in Nmnat2gtBay/gtE mice returned to normal, indicating that the reduction in NAD and NADP caused by low NMNAT2 expression is caused by SARM1 activation. 3. **The impact of low NMNAT2 expression on neurite growth**: - The researchers observed that the growth rate of SCG neurites in Nmnat2gtBay/gtE mice was significantly slowed down, especially after the neurites extended more than a few millimeters. - After knocking out SARM1, the neurite growth rate in Nmnat2gtBay/gtE mice returned to the normal level, further confirming that the neurite growth defect caused by low NMNAT2 expression is SARM1 - dependent. 4. **The impact of nicotinamide riboside (NR) on NAD levels**: - The researchers also explored the impact of NR on NAD levels. The results showed that in the case of low NMNAT2 expression, NR could not increase NAD levels as in wild - type or single - heterozygous mice, but would lead to further consumption of NAD instead. - This phenomenon is also SARM1 - dependent, indicating that under the condition of low NMNAT2 expression, the activation of SARM1 makes NR unable to effectively increase NAD levels. In conclusion, this paper aims to explore how chronic low - level NMNAT2 expression affects axon health and neuron growth by activating SARM1, and reveals the molecular mechanism of this process. These findings are of great significance for understanding the pathogenesis of human axonal diseases.

Chronically low NMNAT2 expression causes sub-lethal SARM1 activation and altered response to nicotinamide riboside in axons

Macrophage Depletion Blocks Congenital SARM1-dependent Neuropathy

Nicotinic Acid Mononucleotide is an Allosteric SARM1 Inhibitor Promoting Axonal Protection.

NMNAT2: an Important Metabolic Enzyme Affecting the Disease Progression

Differentially disrupted spinal cord and muscle energy metabolism in spinal and bulbar muscular atrophy

NMN: The NAD Precursor at the Intersection Between Axon Degeneration and Anti-ageing Therapies

SARM1 is a metabolic sensor activated by an increased NMN/NAD+ ratio to trigger axon degeneration

Programmed axon death executor SARM1 is a multi-functional NAD(P)ase with prominent base exchange activity, all regulated by physiological levels of NMN, NAD, NADP and other metabolites

SARM1 activation induces reversible mitochondrial dysfunction and can be prevented in human neurons by antisense oligonucleotides

Neurotoxins Subvert the Allosteric Activation Mechanism of SARM1 to Induce Neuronal Loss

Neuronal NMNAT2 Overexpression Does Not Achieve Significant Neuroprotection in Experimental Autoimmune Encephalomyelitis/Optic Neuritis.

Restoring Nuclear Entry of Sirtuin 2 in Oligodendrocyte Progenitor Cells Promotes Remyelination During Ageing

NMNAT2 supports vesicular glycolysis via NAD homeostasis to fuel fast axonal transport

Nicotinamide Phosphoribosyltransferase in Smooth Muscle Cells Maintains Genome Integrity, Resists Aortic Medial Degeneration, and is Suppressed in Human Thoracic Aortic Aneurysm Disease

The Role of NMNAT2/SARM1 in Neuropathy Development

Gap Junction Intercellular Communications Regulates Activation of SARM1 and Protects Against Axonal Degeneration

Structural and Mechanistic Regulation of the Pro-degenerative NAD Hydrolase SARM1

Transcriptional Regulation of human NMNAT2: Insights from 3D Genome Sequencing and Bioinformatics

The NAD+ Synthesis Enzyme Nicotinamide Mononucleotide Adenylyltransferase (NMNAT1) Regulates Ribosomal RNA Transcription

NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells

The key role of the NAD biosynthetic enzyme nicotinamide mononucleotide adenylyltransferase in regulating cell functions